An International, Double-blind, Parallel-group, Placebo-controlled, Randomized Study: Evaluation of the Efficacy and Safety of Phenobarbital as Adjunctive Therapy in Participants (> or = 17 to 70 Years Old) With Partial Onset Seizures
| City: |
|
Oklahoma City |
| State: |
|
Oklahoma |
| Zip Code: |
|
73112 |
| Conditions: |
|
Epilepsy |
| Purpose: |
|
Primary:
- to evaluate the efficacy of phenobarbital in reducing seizure frequency.
Secondary:
- to confirm dose response relationship,
- to assess the effects on Type I seizures,
- to assess the safety of phenobarbital
- to assess the drug tolerability.
|
| Study Summary: |
|
Primary:
-to evaluate the efficacy of once daily (OD) administration of 60 mg and 100 mg
phenobarbital, in reducing seizure frequency in participants with partial onset seizures
(Type I seizures; complex or simple with motor symptoms only) not fully controlled despite
treatment with 1 to 3 concomitant anti-epileptic drugs (AEDs) or AEDs with Vagus Nerve
Stimulator (VNS)
Secondary:
- to confirm dose response relationship of 60 and 100 mg phenobarbital doses,
- to assess the effects of phenobarbital on Type I seizures,
- to assess the safety of phenobarbital
- to assess the tolerability of phenobarbital
|
| Criteria: |
|
Inclusion Criteria:
- participants from 17 to 70 years old;
- history of Type I partial onset seizures (complex or simple with motor symptoms
only);
- participants must have had electroencephalogram (EEG), magnetic resonance imaging
(MRI) or computed tomography (CT) with results consistent with diagnosis of
partial-onset seizures;
- participants having at least eight Type I partial onset seizures during 8-week
baseline period;
- participants being uncontrolled while treated by 1 to 3 permitted concomitant
anti-epileptic drug (AED) and/or Vagus Nerve Stimulation (VNS);
- participant has been on a stable dose of their current anti-epileptic treatment
regime
Exclusion Criteria:
- currently taking phenobarbital or primidone;
- currently taking felbamate or vigabatrin;
- history of prior allergic reaction to phenobarbital;
- history of psychogenic seizures;
- history or presence of status epilepticus;
- history or presence of seizures occurring only in clusters;
- participant taking any drug with possible Central Nervous System (CNS) effects except
if stable from 1 month prior Visit 1;
- history of cerebrovascular accident (CVA) or transient ischemic attack (TIA);
- presence of any sign suggesting rapidly progressing brain disorder or brain tumor;
- presence of unstable arteriovenous malformations, meningiomas or other benign tumors;
- history of porphyria;
- presence of clinically significant findings on physical exam, vital signs,
electrocardiogram (ECG) or safety lab assessments, including renal or hepatic
insufficiency;
- history of alcohol or drug abuse within the year prior to screening;
- participant who is known to be non-compliant;
- participant who is male or female who refuses to use an acceptable form of
contraception;
- female who is pregnant or lactating or intends to become pregnant;
- participant who has taken part in any investigational device or product within 2
months prior to the screening visit
|
| NCT ID: |
|
NCT01284556 |
| Primary Contact: |
|
N/A |
| Backup Contact: |
|
N/A |
| Location Contact: |
|
Oklahoma City, Oklahoma 73112
United States
Michael Thomas
Phone: 405-602-3927
Site Status: Recruiting |
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
May 25, 2013 |
| Modifications to this listing: |
|
Only selected fields are shown, please use the link
below to view all information about this clinical trial. |
|
Click to view Full Listing
|